Search results for " Fungal infection"

showing 10 items of 37 documents

From bedside to bench: The missing brick for patients with fungal sepsis

2016

We read with great interest the article by Spec et al. [1] investigating the immunophenotype of T cells from patients with Candida spp. sepsis. This is the first observational study describing the altered immune response of patients with candidemia. The authors included non-neutropenic critically ill patients with candidemia and non-septic controls, and excluded patients with human immunodeficiency virus infection, who had undergone solid or bone marrow transplantation or with other known causes of impaired immune response. The authors hypothesized that their findings may help explain why patients with fungal sepsis show a high mortality despite appropriate antifungal therapy. In our opinio…

0301 basic medicineAdultCD4-Positive T-LymphocytesMalemedicine.medical_specialtyLetterSepsi030106 microbiologyCD8-Positive T-LymphocytesCritical Care and Intensive Care MedicineCommunicable DiseaseSepsis03 medical and health sciences0302 clinical medicineImmunophenotypingImmune systemmedicineHumansIn patientProspective StudiesMED/41 - ANESTESIOLOGIAIntensive care medicineAgedCandidaImmunosuppression TherapyHumans; Communicable Diseases; Sepsis; Critical Care and Intensive Care MedicineImmune statusbusiness.industryCandidemia030208 emergency & critical care medicineMiddle Agedmedicine.diseasePhenotypeObservational studyFemaleFungal sepsisbusinessEmpiric treatmentSepsis fungal infectionHuman
researchProduct

Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodyspla…

2017

This is an observational-retrospective study comparing the real-world outcomes associated with posaconazole vs. itraconazole as prophylaxis treatments. Two hundred and ninety-three patient admissions attributable to 174 patients were included in the study. Patients were treated with itraconazole (n = 114 admissions; 39%) or posaconazole (n = 179; 61%). Antifungal prophylaxis failure (APF) due to treatment-related adverse events (in 34 out of 293 patient admissions; 11.6%) was more frequent in the posaconazole group (6.1% vs. 15.1%; P = 0.024). There were 9 patient admissions for episodes of APF due to probable/proven breakthrough fungal infection (primary endpoint): 6 and 3 in the itraconaz…

0301 basic medicineAdultMalemedicine.medical_specialtyPosaconazoleAntifungal AgentsDrug-Related Side Effects and Adverse ReactionsItraconazole030106 microbiologyDermatologyNeutropenia03 medical and health sciencesInternal medicinemedicineClinical endpointHumansIn patientTreatment FailureAdverse effectAgedRetrospective StudiesInvasive Pulmonary Aspergillosisbusiness.industryMyelodysplastic syndromesGeneral MedicineMiddle AgedTriazolesmedicine.diseaseSurgeryClinical trialLeukemia Myeloid AcuteInfectious DiseasesMyelodysplastic SyndromesFemalePre-Exposure ProphylaxisItraconazolebusinessInvasive Fungal Infectionsmedicine.drugMycoses
researchProduct

Uncertainty about the evidence on untargeted antifungal treatment

2016

N/A

0301 basic medicineAntifungalAntifungal AgentsTraditional medicinebusiness.industrymedicine.drug_classAntifungal therapy; Candidaemia; Invasive fungal infections030106 microbiologyUncertaintysepsis fungal infection03 medical and health sciences0302 clinical medicineCandidaemiaInvasive fungal infectionInvasive fungal infectionsInternal MedicineHumansMedicineAntifungal Agent030212 general & internal medicineMED/41 - ANESTESIOLOGIAbusinessAntifungal therapyHuman
researchProduct

Dying with or because of invasive fungal infection? The role of immunity exhaustion on patient outcome

2016

De Rosa et al. considered clinical scores, biomarkers and their combination as useful aids for an early antifungal treatment and advocated the adoption of de-escalation therapy in an antifungal stewardship approach as a possible key for a better management of these patients. Authors considered the high burden of invasive fungal infections in terms of patient outcomes and costs and focused on current strategies for their optimization.

0301 basic medicineAntifungalmedicine.medical_specialtyEmergency Medicine; Anesthesiology and Pain Medicinebusiness.industrymedicine.drug_class030106 microbiology030208 emergency & critical care medicinemedicine.diseasesepsis fungal infectionOutcome (game theory)03 medical and health sciences0302 clinical medicineAnesthesiology and Pain MedicineAcquired immunodeficiency syndrome (AIDS)ImmunityAntifungal Treatment CORTEGIANI vs. DE ROSA: DEBATE Second RoundEmergency MedicineMedicineMED/41 - ANESTESIOLOGIAbusinessIntensive care medicine
researchProduct

Should we continue to use prediction tools to identify patients at risk of Candida spp. infection? If yes, why?

2016

Background Given the predominance of invasive fungal disease (IFD) amongst the non-immunocompromised adult critically ill population, the potential benefit of antifungal prophylaxis and the lack of generalisable tools to identify high risk patients, the aim of the current study was to describe the epidemiology of IFD in UK critical care units, and to develop and validate a clinical risk prediction tool to identify non-neutropenic, critically ill adult patients at high risk of IFD who would benefit from antifungal prophylaxis. Methods Data on risk factors for, and outcomes from, IFD were collected for consecutive admissions to adult, general critical care units in the UK participating in the…

0301 basic medicineCandida spp; Invasive fungal infections; Sepsismedicine.medical_specialtyAntifungal AgentsSepsi030106 microbiologyMycoseSubgroup analysisCritical Care and Intensive Care Medicinelaw.inventionSepsis03 medical and health sciences0302 clinical medicineInvasive fungal infectionRandomized controlled trialRisk FactorsInvasive fungal infectionslawSepsisIntensive caremedicineHumansAntifungal Agent030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicineCandidaCandida sppProphylaxisbusiness.industryIncidence (epidemiology)Risk FactorCandidiasismedicine.diseaseConfidence intervalCritical careFungalMycosesRelative riskCandida sppCandidiasiCandida spp; Invasive fungal infections; Sepsis; Antifungal Agents; Candida; Humans; Risk Factors; Candidiasis; Mycoses; Critical Care and Intensive Care MedicineInvasive fungal diseasebusinessResearch ArticleHuman
researchProduct

Fungal Infections of the Central Nervous System in Children.

2017

Although uncommon in children, fungal infections of the central nervous system can be devastating and difficult to treat. A better understanding of basic mycologic, immunologic, and pharmacologic processes has led to important advances in the diagnosis and management of these diseases, but their mortality rates remain unacceptably high. In this focused review, we examine the epidemiology and clinical features of the most common fungal pathogens of the central nervous system in children and explore recent advances in diagnosis and antifungal therapy.

0301 basic medicineCentral Nervous Systemmedicine.medical_specialtyAntifungal Agents030106 microbiologyCentral nervous systemAspergillosisHistoplasmosisBlastomycosis03 medical and health sciencesCentral Nervous System Fungal InfectionsEpidemiologymedicineAspergillosisHumansMucormycosisIntensive care medicineChildHistoplasmosisCoccidioidomycosisbusiness.industryMortality rateMucormycosisCandidiasisFungiGeneral MedicineCryptococcosismedicine.diseaseInfectious Diseasesmedicine.anatomical_structurePediatrics Perinatology and Child HealthCryptococcosisbusinessBlastomycosisJournal of the Pediatric Infectious Diseases Society
researchProduct

Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units.

2016

BACKGROUND: Given the predominance of invasive fungal disease (IFD) amongst the non-immunocompromised adult critically ill population, the potential benefit of antifungal prophylaxis and the lack of generalisable tools to identify high risk patients, the aim of the current study was to describe the epidemiology of IFD in UK critical care units, and to develop and validate a clinical risk prediction tool to identify non-neutropenic, critically ill adult patients at high risk of IFD who would benefit from antifungal prophylaxis. METHODS: Data on risk factors for, and outcomes from, IFD were collected for consecutive admissions to adult, general critical care units in the UK participating in t…

0301 basic medicineMalemedicine.medical_specialtyAntifungal AgentsLetterCritical Illness030106 microbiologyPopulationRisk Assessmentlaw.invention03 medical and health sciences0302 clinical medicineMedical microbiologylawRisk FactorsInvasive fungal infectionsSepsisEpidemiologyCandida albicansmedicineHumansCandidiasis InvasiveeducationIntensive care medicineAgedCandidaCandida sppeducation.field_of_studyAdult patientsCritically illbusiness.industryIncidence (epidemiology)IncidenceCandidiasisCandidemia030208 emergency & critical care medicineAntibiotic ProphylaxisMiddle AgedIntensive care unitUnited KingdomIntensive Care UnitsInfectious DiseasesInvasive fungal diseaseFemalebusinessBMC infectious diseases
researchProduct

Invasive candida infections in neonates after major surgery: Current evidence and new directions

2021

Infections represent a serious health problem in neonates. Invasive Candida infections (ICIs) are still a leading cause of mortality and morbidity in neonatal intensive care units (NICUs). Infants hospitalized in NICUs are at high risk of ICIs, because of several risk factors: broad spectrum antibiotic treatments, central catheters and other invasive devices, fungal colonization, and impaired immune responses. In this review we summarize 19 published studies which provide the prevalence of previous surgery in neonates with invasive Candida infections. We also provide an overview of risk factors for ICIs after major surgery, fungal colonization, and innate defense mechanisms against fungi, a…

0301 basic medicineMicrobiology (medical)Antifungalmedicine.medical_specialtymedicine.drug_classInvasive Candida infections030106 microbiologylcsh:MedicineInvasive Candida infectionCandida infections03 medical and health sciencesBroad spectrumNeonatal surgeryinvasive <i>Candida</i> infections0302 clinical medicineInvasive fungal infectionInvasive fungal infectionsIntensive careEpidemiologyFungal colonizationImmunology and AllergyMedicineAntifungal prophylaxi030212 general & internal medicineMolecular BiologyNewbornsGeneral Immunology and Microbiologybusiness.industrylcsh:RImpaired immune responsesNewbornSurgeryNeonatal surgeryInfectious DiseasesSettore MED/20SurgeryAntifungal prophylaxisAntifungal prophylaxis; Invasive Candida infections; Invasive fungal infections; Neonatal surgery; Newborns; Surgerybusiness
researchProduct

Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German …

2020

Background Invasive fungal diseases remain a major cause of morbidity and mortality in cancer patients undergoing intensive cytotoxic therapy. The choice of the most appropriate antifungal treatment (AFT) depends on the fungal species suspected or identified, the patient's risk factors (eg length and depth of granulocytopenia) and the expected side effects. Objectives Since the last edition of recommendations for 'Treatment of invasive fungal infections in cancer patients' of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) in 2013, treatment strategies were gradually moving away from solely empirical therapy of presumed or possib…

0301 basic medicineOncologymedicine.medical_specialtyAntifungal Agents030106 microbiologyMedizinDermatologyNeutropeniaAspergillosis030207 dermatology & venereal diseases03 medical and health sciencesImmunocompromised Host0302 clinical medicineInternal medicineNeoplasmsmedicineHumansHematologybusiness.industryMucormycosisCancerGeneral MedicineGuidelineEvidence-based medicineHematologymedicine.diseaseClinical trialInfectious DiseasesHematologic NeoplasmsPractice Guidelines as TopicbusinessInvasive Fungal InfectionsAgranulocytosis
researchProduct

Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris

2018

Abstract Candida spp. infections are a major cause of morbidity and mortality in critically ill patients. Candida auris is an emerging multi-drug-resistant fungus that is rapidly spreading worldwide. Since the first reports in 2009, many isolates across five continents have been identified as agents of hospital-associated infections. Independent and simultaneous outbreaks of C. auris are becoming a major concern for healthcare and scientific community. Moreover, laboratory misidentification and multi-drug-resistant profiles, rarely observed for other non-albicans Candida species, result in difficult eradication and frequent therapeutic failures of C. auris infections. The aim of this review…

0301 basic medicineSettore MED/07 - Microbiologia E Microbiologia Clinicamedicine.medical_specialty030106 microbiologySettore MED/41 - AnestesiologiaVirulenceAntimicrobial resistanceCritical Care and Intensive Care MedicineMicrobiology03 medical and health sciencesInvasive fungal infectionAntibiotic resistanceEpidemiologymedicineCandidaResistance (ecology)business.industryCritically illlcsh:Medical emergencies. Critical care. Intensive care. First aidCandidemiaOutbreakAntifungal resistancelcsh:RC86-88.9Candida aurisCandida sppC. aurisC. auris Candida Candidemia Invasive fungal infection Antimicrobial resistance Antifungal resistancebusinessJournal of Intensive Care
researchProduct